{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:00:19Z","timestamp":1790085619018,"version":"4.0.1"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopha.2026.119903","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:40:15Z","timestamp":1788561615000},"page":"119903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antibiotics and nanoparticles in Parkinson\u2019s disease: From gut microbiota dysbiosis to neuroprotection and targeted nanotherapies"],"prefix":"10.1016","volume":"203","author":[{"given":"Marie Rose","family":"Frangieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0482-1872","authenticated-orcid":false,"given":"Nour","family":"Fattouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1327-2227","authenticated-orcid":false,"given":"Simona","family":"Sawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119903_bib1","series-title":"Praziquantel: Discovery and Development of an Anthelmintic Drug","first-page":"1","article-title":"A Brief History of the Pharmaceutical Industry","author":"Cabrera","year":"2025"},{"issue":"2","key":"10.1016\/j.biopha.2026.119903_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41579-020-00443-1","article-title":"Proximate and ultimate causes of the bactericidal action of antibiotics","volume":"19","author":"Baquero","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/antibiotics13010099","article-title":"Tailored pre-operative antibiotic prophylaxis to prevent post-operative surgical site infections in general surgery","volume":"13","author":"Vierra","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.biopha.2026.119903_bib4","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.2147\/IDR.S428837","article-title":"Potential causes of spread of antimicrobial resistance and preventive measures in one health perspective-a review","author":"Endale","year":"2023","journal-title":"Infect. Drug. Resist."},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev-micro-091313-103456","article-title":"Effects of antibiotics on human microbiota and subsequent disease","volume":"68","author":"Keeney","year":"2014","journal-title":"Annu. Rev. Microbiol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119903_bib6","first-page":"1","article-title":"Exploring the gut-brain axis: a comprehensive review of interactions between the gut microbiota and the central nervous system","volume":"6","author":"Bakshi","year":"2024","journal-title":"Int. J. Multidiscip. Res."},{"issue":"37","key":"10.1016\/j.biopha.2026.119903_bib7","doi-asserted-by":"crossref","first-page":"10609","DOI":"10.3748\/wjg.v21.i37.10609","article-title":"and B. Bonaz, Brain-gut-microbiota axis in Parkinson's disease.","volume":"21","author":"Mulak","year":"2015","journal-title":"World J. Gastroenterol. WJG"},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12974-019-1528-y","article-title":"Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson\u2019s disease","volume":"16","author":"Lin","year":"2019","journal-title":"J. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41531-021-00156-z","article-title":"Meta-analysis of the Parkinson\u2019s disease gut microbiome suggests alterations linked to intestinal inflammation","volume":"7","author":"Romano","year":"2021","journal-title":"npj Park. 's. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2026.119903_bib10","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3892\/mmr.2021.12374","article-title":"Roles of \u03b1-synuclein in gastrointestinal microbiome dysbiosis-related Parkinson's disease progression","volume":"24","author":"Lei","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2026.119903_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fnins.2019.00369","article-title":"Alpha-synuclein pathology and the role of the microbiota in Parkinson\u2019s disease","volume":"13","author":"Fitzgerald","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.biopha.2026.119903_bib12","article-title":"Gut microbiota: a novel therapeutic target for Parkinson\u2019s disease","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119903_bib13","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1007\/s12035-024-04584-9","article-title":"Parkinson's disease and the microbiota-gut-brain axis: metabolites, mechanisms, and innovative therapeutic strategies targeting the gut microbiota","volume":"62","author":"Ran","year":"2025","journal-title":"Mol. Neurobiol."},{"issue":"20","key":"10.1016\/j.biopha.2026.119903_bib14","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.3390\/nu15204365","article-title":"Gut microbiota composition in patients with neurodegenerative disorders (Parkinson\u2019s and Alzheimer\u2019s) and healthy controls: a systematic review","volume":"15","author":"Heravi","year":"2023","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.biopha.2026.119903_bib15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/futurepharmacol4020020","article-title":"Nanotechnology-driven therapeutic innovations in neurodegenerative disorders: a focus on Alzheimer\u2019s and Parkinson\u2019s disease","volume":"4","author":"Krsek","year":"2024","journal-title":"Future Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119903_bib16","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s13346-025-01799-8","article-title":"Nanotechnology in Parkinson\u2019s Disease: overcoming drug delivery challenges and enhancing therapeutic outcomes","volume":"16","author":"Ali","year":"2026","journal-title":"Drug. Deliv. Transl. Res."},{"issue":"33","key":"10.1016\/j.biopha.2026.119903_bib17","doi-asserted-by":"crossref","first-page":"35223","DOI":"10.1021\/acsomega.4c01774","article-title":"Current overview on the use of nanosized drug delivery systems in the treatment of neurodegenerative diseases","volume":"9","author":"Ozceylan","year":"2024","journal-title":"ACS Omega"},{"issue":"3","key":"10.1016\/j.biopha.2026.119903_bib18","first-page":"51","article-title":"M.d.C. Rodr\u00edguez-Salazar, S.Y. Silva-Belmares, and H. Aguayo-Morales, Nanoparticle-based strategies to enhance catecholaminergic drug delivery for neuropsychiatric disorders: Advances, challenges, and therapeutic opportunities. Future","volume":"5","author":"Cobos-Puc","year":"2025","journal-title":"Pharmacology"},{"issue":"5","key":"10.1016\/j.biopha.2026.119903_bib19","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3390\/pharmaceutics16050670","article-title":"A review of recent developments in biopolymer nano-based drug delivery systems with antioxidative properties: Insights into the last five years","volume":"16","author":"Stevanovi\u0107","year":"2024","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.biopha.2026.119903_bib20","article-title":"Development of nanoparticle-based drug delivery system for inflammation treatment and diagnosis","volume":"2","author":"Qin","year":"2023","journal-title":"MedCommBiomater. Appl."},{"issue":"4","key":"10.1016\/j.biopha.2026.119903_bib21","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.3390\/ijms25042360","article-title":"Gold nanoparticles in neurological diseases: a review of neuroprotection","volume":"25","author":"Chiang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2026.119903_bib22","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.freeradbiomed.2011.06.006","article-title":"Neuroprotective mechanisms of cerium oxide nanoparticles in a mouse hippocampal brain slice model of ischemia","volume":"51","author":"Estevez","year":"2011","journal-title":"Free. Radic. Biol. Med."},{"issue":"11","key":"10.1016\/j.biopha.2026.119903_bib23","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20241102","article-title":"Neuroprotective properties of zinc oxide nanoparticles: therapeutic implications for Parkinson's disease","volume":"44","author":"Tang","year":"2024","journal-title":"Biosci. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2026.119903_bib24","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.3390\/ijms26083915","article-title":"A review of the neuroprotective properties of exosomes derived from stem cells and exosome-coated nanoparticles for treating neurodegenerative diseases and stroke","volume":"26","author":"Yang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib25","doi-asserted-by":"crossref","first-page":"a008862","DOI":"10.1101\/cshperspect.a008862","article-title":"The history of Parkinson's disease: early clinical descriptions and neurological therapies","volume":"1","author":"Goetz","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"9","key":"10.1016\/j.biopha.2026.119903_bib26","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.3390\/biomedicines12092121","article-title":"Navigating the neurobiology of Parkinson\u2019s: the impact and potential of \u03b1-synuclein","volume":"12","author":"Paul\u0117kas","year":"2024","journal-title":"Biomedicines"},{"issue":"6(12","key":"10.1016\/j.biopha.2026.119903_bib27","article-title":"Parkinson's Disease: The Epidemiology, Risk Factors, Molecular Pathogenesis, Prevention, and Therapy","volume":"2020","author":"Guo","year":"2025","journal-title":"MedComm"},{"issue":"23","key":"10.1016\/j.biopha.2026.119903_bib28","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1111\/febs.12335","article-title":"The hallmarks of Parkinson's disease","volume":"280","author":"Antony","year":"2013","journal-title":"Febs J."},{"issue":"3","key":"10.1016\/j.biopha.2026.119903_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S095925981200007X","article-title":"Parkinson's disease\u2013pathology, aetiology and diagnosis","volume":"22","author":"Macphee","year":"2012","journal-title":"Rev. Clin. Gerontol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119903_bib30","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/brain\/awz120","article-title":"Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system","volume":"142","author":"Mart\u00edn-Bastida","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2026.119903_bib31","first-page":"93","article-title":"a-synuclein in Parkinson's disease","volume":"4","author":"Leonidas","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119903_bib32","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson's disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2026.119903_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/B978-0-323-85555-6.00001-1","article-title":"Ezzat, K., A. Sturchio, and A.J. Espay, The shift to a proteinopenia paradigm in neurodegeneration.","volume":"193","year":"2023","journal-title":"Handb. Clin. Neurol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119903_bib34","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000214346","article-title":"CSF \u03b1-synuclein seed amplification assays and Alzheimer disease biomarkers in dementia with Lewy bodies: presentation and progression","volume":"105","author":"Coughlin","year":"2025","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.biopha.2026.119903_bib35","first-page":"503","article-title":"Cutaneous alpha-synuclein from paraffin embedded autopsy specimens in Parkinson\u2019s disease","volume":"7","author":"Gibbons","year":"2017","journal-title":"J. Park. \u2019S. Dis."},{"issue":"11","key":"10.1016\/j.biopha.2026.119903_bib36","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/aje\/kwr451","article-title":"Caffeine intake, smoking, and risk of Parkinson disease in men and women","volume":"175","author":"Liu","year":"2012","journal-title":"Am. J. Epidemiol."},{"issue":"1-4","key":"10.1016\/j.biopha.2026.119903_bib37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000333222","article-title":"Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: a nationwide epidemiological study from Sweden","volume":"10","author":"Li","year":"2012","journal-title":"Neurodegener. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2026.119903_bib38","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4103\/joacp.JOACP_349_15","article-title":"Action and resistance mechanisms of antibiotics: A guide for clinicians","volume":"33","author":"Kapoor","year":"2017","journal-title":"J. Anaesthesiol. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119903_bib39","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1039\/C6MD00585C","article-title":"A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics","volume":"8","author":"Sarkar","year":"2017","journal-title":"Medchemcomm"},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib40","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/s41467-017-02118-7","article-title":"Inhibition of D-Ala:D-Ala ligase through a phosphorylated form of the antibiotic D-cycloserine","volume":"8","author":"Batson","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119903_bib41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/antibiotics15040351","article-title":"Antibiotic Mechanisms and Resistance: Molecular Insights and Therapeutic Strategies","volume":"15","author":"Ma","year":"2026","journal-title":"Antibiotics"},{"key":"10.1016\/j.biopha.2026.119903_bib42","series-title":"Macromolecular Protein Complexes II: Structure and Function","first-page":"273","article-title":"Penicillin-Binding Proteins (PBPs) and Bacterial Cell Wall Elongation Complexes","author":"Miyachiro","year":"2019"},{"key":"10.1016\/j.biopha.2026.119903_bib43","author":"Johansson","year":"2012","journal-title":"Rate Accuracy Bact. Protein Synth."},{"key":"10.1016\/j.biopha.2026.119903_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1305294","article-title":"Antibiotic action and resistance: updated review of mechanisms, spread, influencing factors, and alternative approaches for combating resistance","volume":"14","author":"Halawa","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib45","article-title":"DNA replication: Mechanisms and therapeutic interventions for diseases","volume":"4","author":"Song","year":"2023","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.biopha.2026.119903_bib46","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.biopha.2018.04.021","article-title":"DNA gyrase inhibitors: Progress and synthesis of potent compounds as antibacterial agents","volume":"103","author":"Khan","year":"2018","journal-title":"Biomed. & Pharmacother."},{"issue":"6","key":"10.1016\/j.biopha.2026.119903_bib47","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1021\/cb500154m","article-title":"Gyramides prevent bacterial growth by inhibiting DNA gyrase and altering chromosome topology","volume":"9","author":"Rajendram","year":"2014","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2016.08.009","article-title":"One-carbon metabolism in health and disease","volume":"25","author":"Ducker","year":"2017","journal-title":"Cell. Metab."},{"key":"10.1016\/j.biopha.2026.119903_bib49","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/biom14101263","article-title":"Mechanistic Insights into Clinically Relevant Ribosome-Targeting Antibiotics","volume":"14","author":"Krawczyk","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2026.119903_bib50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tma.2025.02.002","article-title":"Curli protein: A potential contributor to \u03b1-synucleopathy in Parkinson's disease","volume":"9","author":"Ghosh","year":"2025","journal-title":"Transl. Med. Aging"},{"issue":"11","key":"10.1016\/j.biopha.2026.119903_bib51","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1099\/mic.0.040618-0","article-title":"Long-term impacts of antibiotic exposure on the human intestinal microbiota","volume":"156","author":"Jernberg","year":"2010","journal-title":"Microbiology"},{"issue":"6","key":"10.1016\/j.biopha.2026.119903_bib52","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.molmed.2016.04.003","article-title":"Antibiotic-induced changes in the intestinal microbiota and disease","volume":"22","author":"Becattini","year":"2016","journal-title":"Trends Mol. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119903_bib53","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1152\/physrev.00018.2018","article-title":"The microbiota-gut-brain axis","volume":"99","author":"Cryan","year":"2019","journal-title":"Physiol. Rev."},{"issue":"6","key":"10.1016\/j.biopha.2026.119903_bib54","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","article-title":"Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease","volume":"167","author":"Sampson","year":"2016","journal-title":"cell"},{"issue":"3","key":"10.1016\/j.biopha.2026.119903_bib55","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/mds.26069","article-title":"Gut microbiota are related to Parkinson's disease and clinical phenotype","volume":"30","author":"Scheperjans","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2026.119903_bib56","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.parkreldis.2016.08.019","article-title":"Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls","volume":"32","author":"Unger","year":"2016","journal-title":"Park. & Relat. Disord."},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cmet.2016.06.016","article-title":"Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: a randomized double-blind placebo-controlled trial","volume":"24","author":"Reijnders","year":"2016","journal-title":"Cell. Metab."},{"issue":"6","key":"10.1016\/j.biopha.2026.119903_bib58","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.chom.2018.05.003","article-title":"Gut microbiota regulation of tryptophan metabolism in health and disease","volume":"23","author":"Agus","year":"2018","journal-title":"Cell. host & Microbe"},{"issue":"7","key":"10.1016\/j.biopha.2026.119903_bib59","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41574-024-00966-0","article-title":"The individual response to antibiotics and diet\u2014insights into gut microbial resilience and host metabolism","volume":"20","author":"Vliex","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119903_bib60","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1093\/brain\/awab156","article-title":"The role of gut dysbiosis in Parkinson\u2019s disease: mechanistic insights and therapeutic options","volume":"144","author":"Wang","year":"2021","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.biopha.2026.119903_bib61","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1111\/ene.15671","article-title":"Gut microbiota dysbiosis in Parkinson disease: A systematic review and pooled analysis","volume":"30","author":"Kleine Bardenhorst","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119903_bib62","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/mds.25736","article-title":"Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease","volume":"29","author":"Kelly","year":"2014","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.biopha.2026.119903_bib63","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41582-022-00681-2","article-title":"The microbiome\u2013gut\u2013brain axis in Parkinson disease\u2014from basic research to the clinic","volume":"18","author":"Tan","year":"2022","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119903_bib64","first-page":"1219","article-title":"Alteration of gut microbial metabolites in the systemic circulation of patients with Parkinson\u2019s disease","volume":"12","author":"Chen","year":"2022","journal-title":"J. Park. \u2019S. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib65","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev-biochem-071322-021330","article-title":"Polyamines in Parkinson's disease: balancing between neurotoxicity and neuroprotection","volume":"92","author":"Vrijsen","year":"2023","journal-title":"Annu. Rev. Biochem."},{"issue":"14","key":"10.1016\/j.biopha.2026.119903_bib66","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.3390\/jcm13144130","article-title":"The brain\u2013gut axis, an important player in Alzheimer and Parkinson disease: a narrative review","volume":"13","author":"Caradonna","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2026.119903_bib67","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.53111","article-title":"A gut bacterial amyloid promotes \u03b1-synuclein aggregation and motor impairment in mice","volume":"9","author":"Sampson","year":"2020","journal-title":"elife"},{"key":"10.1016\/j.biopha.2026.119903_bib68","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ebiom.2019.05.064","article-title":"Gut microbiota in Parkinson's disease: temporal stability and relations to disease progression","volume":"44","author":"Aho","year":"2019","journal-title":"EBioMedicine"},{"issue":"5556","key":"10.1016\/j.biopha.2026.119903_bib69","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1126\/science.1067484","article-title":"Role of Escherichia coli curli operons in directing amyloid fiber formation","volume":"295","author":"Chapman","year":"2002","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.biopha.2026.119903_bib70","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.bbamcr.2013.09.010","article-title":"Curli biogenesis: order out of disorder","volume":"1843","author":"Evans","year":"2014","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Cell Research"},{"issue":"12","key":"10.1016\/j.biopha.2026.119903_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006654","article-title":"The role of microbial amyloid in neurodegeneration","volume":"13","author":"Friedland","year":"2017","journal-title":"PLoS. Pathog."},{"issue":"5","key":"10.1016\/j.biopha.2026.119903_bib72","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/glia.20467","article-title":"Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration","volume":"55","author":"Qin","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2026.119903_bib73","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.3389\/fmicb.2026.1748742","article-title":"Next-generation bacteriophage therapeutic systems: CRISPR-based engineering, near-infrared bioimaging, and precision strategies for treating multidrug-resistant and extensively drug-resistant bacterial infections","volume":"17","author":"Piracha","year":"2026","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib74","doi-asserted-by":"crossref","first-page":"34477","DOI":"10.1038\/srep34477","article-title":"Exposure to the functional bacterial amyloid protein curli enhances alpha-synuclein aggregation in aged Fischer 344 rats and Caenorhabditis elegans","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119903_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1241418","article-title":"Emerging therapeutic role of gut microbial extracellular vesicles in neurological disorders","volume":"17","author":"Sun","year":"2023","journal-title":"Front. Neurosci."},{"issue":"12","key":"10.1016\/j.biopha.2026.119903_bib76","article-title":"C9-Functionalized Doxycycline Analogs as Drug Candidates to Prevent Pathological \u03b1-Synuclein Aggregation and Neuroinflammation in Parkinson's Disease Degeneration","volume":"19","author":"Rose","year":"2024","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antibiotics1010001","article-title":"Classification framework and chemical biology of tetracycline-structure-based drugs","volume":"1","author":"Fuoco","year":"2012","journal-title":"Antibiotics"},{"issue":"3","key":"10.1016\/j.biopha.2026.119903_bib78","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3390\/antiox12030575","article-title":"Rescue of dopamine neurons from iron-dependent ferroptosis by doxycycline and demeclocycline and their non-antibiotic derivatives","volume":"12","author":"Tourville","year":"2023","journal-title":"Antioxidants"},{"issue":"8","key":"10.1016\/j.biopha.2026.119903_bib79","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3390\/cells10082163","article-title":"The chemically-modified tetracycline COL-3 and its parent compound doxycycline prevent microglial inflammatory responses by reducing glucose-mediated oxidative stress","volume":"10","author":"Ferreira Junior","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.biopha.2026.119903_bib80","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.2001.19.2.584","article-title":"Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer","volume":"19","author":"Reed","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119903_bib81","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1007\/s00213-013-3400-6","article-title":"The effects of the \u03b2-lactam antibiotic, ceftriaxone, on forepaw stepping and l-DOPA-induced dyskinesia in a rodent model of Parkinson\u2019s disease","volume":"231","author":"Kelsey","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopha.2026.119903_bib82","unstructured":"Neville, C.B., The \u03b2-lactam antibiotic ceftriaxone as a treatment for the symptoms of Parkinson\u2019s disease and L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. 2012."},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib83","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9424582","article-title":"Neuroprotective Effect of Ceftriaxone on MPTP-Induced Parkinson\u2019s Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota","volume":"2021","author":"Zhou","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.biopha.2026.119903_bib84","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.neuro.2014.05.009","article-title":"Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats","volume":"44","author":"Bisht","year":"2014","journal-title":"Neurotoxicology"},{"issue":"2","key":"10.1016\/j.biopha.2026.119903_bib85","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pathophys.2017.02.001","article-title":"Ceftriaxone attenuates glutamate-mediated neuro-inflammation and restores BDNF in MPTP model of Parkinson\u2019s disease in rats","volume":"24","author":"Kaur","year":"2017","journal-title":"Pathophysiology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib86","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1021\/cn200072h","article-title":"Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats","volume":"3","author":"Leung","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2026.119903_bib87","unstructured":"Corporation, B. To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia, [ClinicalTrials.gov identifier NCT03413384]. 2026; Available from: https:\/\/clinicaltrials.gov\/study\/NCT03413384?tab=study."},{"key":"10.1016\/j.biopha.2026.119903_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109564","article-title":"Dysbiosis in Parkinson\u2019s disease might be triggered by certain antibiotics","volume":"137","author":"Tern\u00e1k","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"9","key":"10.1016\/j.biopha.2026.119903_bib89","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3390\/antibiotics11091145","article-title":"Antibiotic consumption patterns in European countries are associated with the prevalence of Parkinson\u2019s disease; the possible augmenting role of the narrow-spectrum penicillin","volume":"11","author":"Tern\u00e1k","year":"2022","journal-title":"Antibiotics"},{"issue":"3","key":"10.1016\/j.biopha.2026.119903_bib90","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mds.27924","article-title":"Antibiotic exposure and risk of Parkinson's disease in Finland: a nationwide case-control study","volume":"35","author":"Mertsalmi","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2026.119903_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107081","article-title":"Effects of antimicrobial exposure on the risk of Parkinson's disease","volume":"127","author":"Pal","year":"2024","journal-title":"Park. & Relat. Disord."},{"key":"10.1016\/j.biopha.2026.119903_bib92","doi-asserted-by":"crossref","DOI":"10.1159\/000545218","article-title":"Insights on the Association between Antimicrobial Use and Risk of Parkinson\u2019s Disease: A Systematic Review and Meta-Analysis","author":"Abouelmagd","year":"2025","journal-title":"Neuroepidemiology"},{"issue":"4","key":"10.1016\/j.biopha.2026.119903_bib93","article-title":"The Impact of Antibiotic Therapy on Intestinal Microbiota: Dysbiosis, Antibiotic Resistance, and Restoration Strategies","volume":"14","author":"Cusumano","year":"2025","journal-title":"Antibiot. (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib94","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41531-025-00900-9","article-title":"The profile of gastrointestinal dysfunction in prodromal to late-stage Parkinson's disease","volume":"11","author":"Camacho","year":"2025","journal-title":"NPJ Park. Dis."},{"key":"10.1016\/j.biopha.2026.119903_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2025.07.003","article-title":"Parkinson\u2019s disease and the gut microbiota connection: unveiling dysbiosis and exploring therapeutic horizons","volume":"581","author":"Yadav","year":"2025","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.biopha.2026.119903_bib96","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s13365-018-0707-4","article-title":"Impact of infection on risk of Parkinson\u2019s disease: a quantitative assessment of case-control and cohort studies","volume":"25","author":"Meng","year":"2019","journal-title":"J. Neurovirology"},{"issue":"9","key":"10.1016\/j.biopha.2026.119903_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004092","article-title":"Hospital-treated infections in early-and mid-life and risk of Alzheimer\u2019s disease, Parkinson\u2019s disease, and amyotrophic lateral sclerosis: a nationwide nested case-control study in Sweden","volume":"19","author":"Sun","year":"2022","journal-title":"PLoS. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119903_bib98","doi-asserted-by":"crossref","first-page":"fcae098","DOI":"10.1093\/braincomms\/fcae098","article-title":"Hospital-treated infections and subsequent Parkinson\u2019s disease risk: a register-based sibling comparison study","volume":"6","author":"Vingeliene","year":"2024","journal-title":"Brain Commun."},{"key":"10.1016\/j.biopha.2026.119903_bib99","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.bbi.2024.06.016","article-title":"Hospital-treated infectious diseases, infection burden and risk of Parkinson disease: An observational and Mendelian randomization study","volume":"120","author":"Zheng","year":"2024","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib100","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200400","article-title":"Antibiotic exposure and risk of parkinson disease in South Korea: a nationally representative retrospective cohort study","volume":"15","author":"Kim","year":"2025","journal-title":"Neurol. Clin. Pract."},{"issue":"21","key":"10.1016\/j.biopha.2026.119903_bib101","doi-asserted-by":"crossref","first-page":"e2068","DOI":"10.1212\/WNL.0000000000207899","article-title":"Association between use of any of the drugs prescribed in Norway and the subsequent risk of Parkinson disease: a drug-wide association study","volume":"101","author":"Romanowska","year":"2023","journal-title":"Neurology"},{"issue":"7484","key":"10.1016\/j.biopha.2026.119903_bib102","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature12820","article-title":"Diet rapidly and reproducibly alters the human gut microbiome","volume":"505","author":"David","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib103","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12967-017-1175-y","article-title":"Influence of diet on the gut microbiome and implications for human health","volume":"15","author":"Singh","year":"2017","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119903_bib104","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.tim.2011.11.005","article-title":"Diversity, biogenesis and function of microbial amyloids","volume":"20","author":"Blanco","year":"2012","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.biopha.2026.119903_bib105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fncel.2014.00211","article-title":"Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease","volume":"8","author":"Cabezas","year":"2014","journal-title":"Front. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/scipharm87010006","article-title":"Overcoming the Blood\u2013Brain Barrier. Challenges and Tricks for CNS Drug Delivery","volume":"87","author":"Bors","year":"2019","journal-title":"Sci. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2026.119903_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17050661","article-title":"Advancing Brain Targeting: Cost-Effective Surface-Modified Nanoparticles for Faster Market Entry","volume":"17","author":"Gomes","year":"2025","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.biopha.2026.119903_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084153","article-title":"Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology","volume":"23","author":"Hersh","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119903_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.587012","article-title":"Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization","volume":"7","author":"Sanita","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"7","key":"10.1016\/j.biopha.2026.119903_bib110","article-title":"Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles' Physicochemical Properties on Responses in Biological Systems","volume":"15","author":"Yusuf","year":"2023","journal-title":"Polym. (Basel)"},{"key":"10.1016\/j.biopha.2026.119903_bib111","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bmt.2023.01.001","article-title":"Acid-labile chemical bonds-based nanoparticles for endosome escape and intracellular delivery","volume":"3","author":"Cheng","year":"2023","journal-title":"Biomed. Technol."},{"key":"10.1016\/j.biopha.2026.119903_bib112","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jconrel.2023.06.026","article-title":"Levodopa-loaded nanoparticles for the treatment of Parkinson's disease","volume":"360","author":"van Vliet","year":"2023","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.biopha.2026.119903_bib113","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1016\/j.apsb.2024.05.010","article-title":"Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy","volume":"14","author":"Peng","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.biopha.2026.119903_bib114","doi-asserted-by":"crossref","first-page":"246","DOI":"10.5607\/en.2014.23.3.246","article-title":"Increasing the Efficiency of Parkinson's Disease Treatment Using a poly(lactic-co-glycolic acid) (PLGA) Based L-DOPA Delivery System","volume":"23","author":"Gambaryan","year":"2014","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.biopha.2026.119903_bib115","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.actbio.2020.03.021","article-title":"Self-assembled polydopamine nanoparticles improve treatment in Parkinson's disease model mice and suppress dopamine-induced dyskinesia","volume":"109","author":"Vong","year":"2020","journal-title":"Acta Biomater."},{"issue":"8","key":"10.1016\/j.biopha.2026.119903_bib116","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.nano.2018.08.004","article-title":"Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease","volume":"14","author":"Sridhar","year":"2018","journal-title":"Nanomedicine"},{"issue":"2","key":"10.1016\/j.biopha.2026.119903_bib117","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/jps.22285","article-title":"Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations","volume":"100","author":"Tsai","year":"2011","journal-title":"J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2026.119903_bib118","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s11095-007-9514-y","article-title":"Solid lipid nanoparticles as delivery systems for bromocriptine","volume":"25","author":"Esposito","year":"2008","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib119","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/10717544.2012.752421","article-title":"Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach","volume":"20","author":"Pardeshi","year":"2013","journal-title":"Drug. Deliv."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119903_bib120","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijpharm.2011.10.039","article-title":"Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation","volume":"422","author":"Azeem","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib121","article-title":"Vitamin E Loaded Naringenin Nanoemulsion via Intranasal Delivery for the Management of Oxidative Stress in a 6-OHDA Parkinson\u2019s Disease Model","volume":"2019","author":"Gaba","year":"2019","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.biopha.2026.119903_bib122","article-title":"Recuperative effect of metformin loaded polydopamine nanoformulation promoting EZH2 mediated proteasomal degradation of phospho-alpha-synuclein in Parkinson's disease model","volume":"24","author":"Sardoiwala","year":"2020","journal-title":"Nanomedicine"},{"issue":"4","key":"10.1016\/j.biopha.2026.119903_bib123","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00210-018-1474-8","article-title":"Improved neuroprotective effect of resveratrol nanoparticles as evinced by abrogation of rotenone-induced behavioral deficits and oxidative and mitochondrial dysfunctions in rat model of Parkinson's disease","volume":"391","author":"Palle","year":"2018","journal-title":"Naunyn Schmiede Arch. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119903_bib124","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/10837450.2020.1740257","article-title":"vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery","volume":"25","author":"Arisoy","year":"2020","journal-title":"Pharm. Dev. Technol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119903_bib125","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/app8040474","article-title":"Neuroprotective investigation of chitosan nanoparticles for dopamine delivery","volume":"8","author":"Ragusa","year":"2018","journal-title":"Appl. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib126","doi-asserted-by":"crossref","first-page":"15185","DOI":"10.1038\/s41598-021-94175-8","article-title":"Dopamine-loaded nanoparticle systems circumvent the blood\u2013brain barrier restoring motor function in mouse model for Parkinson\u2019s Disease","volume":"11","author":"Monge-Fuentes","year":"2021","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2026.119903_bib127","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7150\/thno.16562","article-title":"Inhibition by Multifunctional Magnetic Nanoparticles Loaded with Alpha-Synuclein RNAi Plasmid in a Parkinson's Disease Model","volume":"7","author":"Niu","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2026.119903_bib128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.omtn.2017.08.013","article-title":"Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce alpha-Synuclein Expression in a Model of Parkinson's Disease","volume":"9","author":"Helmschrodt","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"10","key":"10.1016\/j.biopha.2026.119903_bib129","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1007\/s11095-013-1005-8","article-title":"Angiopep-conjugated nanoparticles for targeted long-term gene therapy of Parkinson\u2019s disease","volume":"30","author":"Huang","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2026.119903_bib130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.actbio.2016.12.048","article-title":"Polylysine-modified polyethylenimine (PEI-PLL) mediated VEGF gene delivery protects dopaminergic neurons in cell culture and in rat models of Parkinson's Disease (PD)","volume":"54","author":"Sheikh","year":"2017","journal-title":"Acta Biomater."},{"issue":"4","key":"10.1016\/j.biopha.2026.119903_bib131","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.nano.2018.01.020","article-title":"Neuroprotective effect of gold nanoparticles composites in Parkinson's disease model","volume":"14","author":"Hu","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biopha.2026.119903_bib132","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jconrel.2016.06.005","article-title":"MicroRNA-124 loaded nanoparticles enhance brain repair in Parkinson's disease","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"issue":"30","key":"10.1016\/j.biopha.2026.119903_bib133","doi-asserted-by":"crossref","first-page":"9408","DOI":"10.1002\/anie.201805052","article-title":"Ceria Nanoparticle Systems for Selective Scavenging of Mitochondrial, Intracellular, and Extracellular Reactive Oxygen Species in Parkinson's Disease","volume":"57","author":"Kwon","year":"2018","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biopha.2026.119903_bib134","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neuint.2017.05.011","article-title":"Cerium oxide nanoparticles could ameliorate behavioral and neurochemical impairments in 6-hydroxydopamine induced Parkinson's disease in rats","volume":"108","author":"Hegazy","year":"2017","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.biopha.2026.119903_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111302","article-title":"Effects of gold nanoparticles administration through behavioral and oxidative parameters in animal model of Parkinson\u2019s disease","volume":"196","author":"da Silva C\u00f3rneo","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"2","key":"10.1016\/j.biopha.2026.119903_bib136","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/acs.biomac.6b01547","article-title":"Iron Chelation Nanoparticles with Delayed Saturation as an Effective Therapy for Parkinson Disease","volume":"18","author":"Wang","year":"2017","journal-title":"Biomacromolecules"},{"issue":"1","key":"10.1016\/j.biopha.2026.119903_bib137","doi-asserted-by":"crossref","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","article-title":"The blood-brain barrier","volume":"7","author":"Daneman","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119903_bib138","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15112599","article-title":"Non-Invasive Drug Delivery across the Blood-Brain Barrier: A Prospective Analysis","volume":"15","author":"Niazi","year":"2023","journal-title":"Pharmaceutics"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600939X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600939X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:06:59Z","timestamp":1790082419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222600939X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":138,"alternative-id":["S075333222600939X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119903","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotics and nanoparticles in Parkinson\u2019s disease: From gut microbiota dysbiosis to neuroprotection and targeted nanotherapies","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119903"}}